Total Payments
$3,793
2024 Payments
$355.23
Companies
36
Transactions
166
Medicare Patients
3,474
Medicare Billing
$778,687
Payment Breakdown by Category
Food & Beverage$3,256 (85.8%)
Research$514.44 (13.6%)
Education$22.70 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,256 | 162 | 85.8% |
| Unspecified | $514.44 | 1 | 13.6% |
| Education | $22.70 | 3 | 0.6% |
Payments by Type
General
$3,279
165 transactions
Research
$514.44
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka Pharmaceutical Co., Ltd. | $514.44 | 1 | $0 (2018) |
| Mallinckrodt Enterprises LLC | $440.10 | 22 | $0 (2019) |
| Horizon Therapeutics plc | $378.33 | 15 | $0 (2023) |
| Vifor Pharma, Inc. | $335.22 | 14 | $0 (2024) |
| Amgen Inc. | $324.28 | 21 | $0 (2024) |
| Fresenius USA Marketing, Inc. | $241.88 | 13 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $170.59 | 7 | $0 (2022) |
| Otsuka America Pharmaceutical, Inc. | $149.60 | 9 | $0 (2024) |
| Relypsa, Inc. | $131.61 | 6 | $0 (2019) |
| Keryx Biopharmaceuticals, Inc. | $126.92 | 6 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $355.23 | 17 | Vifor Pharma, Inc. ($83.10) |
| 2023 | $268.95 | 13 | Vifor Pharma, Inc. ($80.59) |
| 2022 | $393.34 | 14 | Horizon Therapeutics plc ($131.81) |
| 2021 | $308.73 | 18 | Vifor Pharma, Inc. ($101.26) |
| 2020 | $197.56 | 12 | AstraZeneca Pharmaceuticals LP ($48.24) |
| 2019 | $697.66 | 30 | Horizon Therapeutics plc ($168.37) |
| 2018 | $1,091 | 35 | Otsuka Pharmaceutical Co., Ltd. ($514.44) |
| 2017 | $480.48 | 27 | Mallinckrodt LLC ($204.09) |
All Payment Transactions
166 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/21/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $27.51 | General |
| Category: Cardio-renal | ||||||
| 11/20/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $14.06 | General |
| Category: NEPHROLOGY | ||||||
| 11/16/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $13.84 | General |
| Category: NEPHROLOGY | ||||||
| 10/23/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $21.06 | General |
| Category: Phosphate binder for ESRD | ||||||
| 10/02/2024 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $30.12 | General |
| Category: Hyperkalemia | ||||||
| 08/30/2024 | Medtronic, Inc. | SYMPLICITY G3 (Device) | Food and Beverage | In-kind items and services | $15.49 | General |
| Category: Renal Denervation System | ||||||
| 08/27/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $4.15 | General |
| 07/24/2024 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $26.03 | General |
| Category: Hyperkalemia | ||||||
| 07/10/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $21.25 | General |
| Category: HIV | ||||||
| 07/10/2024 | Amgen Inc. | Aranesp (Biological), Parsabiv, TAVNEOS | Food and Beverage | In-kind items and services | $20.22 | General |
| Category: Nephrology | ||||||
| 06/05/2024 | Ultragenyx Pharmaceutical Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $24.13 | General |
| Category: XLH Metabolic Bone Disorder | ||||||
| 05/08/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $18.74 | General |
| Category: NEPHROLOGY | ||||||
| 04/24/2024 | Fresenius USA Marketing, Inc. | — | Food and Beverage | In-kind items and services | $24.28 | General |
| 04/19/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $27.46 | General |
| Category: Rare Disease | ||||||
| 01/29/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $19.67 | General |
| Category: Inflammation/Rare Disease | ||||||
| 01/10/2024 | Fresenius USA Marketing, Inc. | — | Food and Beverage | In-kind items and services | $20.27 | General |
| 01/04/2024 | Vifor Pharma, Inc. | — | Food and Beverage | In-kind items and services | $26.95 | General |
| 11/30/2023 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $14.09 | General |
| Category: HIV | ||||||
| 11/15/2023 | Amgen Inc. | Parsabiv (Drug), TAVNEOS | Food and Beverage | In-kind items and services | $28.32 | General |
| Category: Nephrology | ||||||
| 10/18/2023 | Calliditas Therapeutics US Inc. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $17.09 | General |
| Category: Nephrology | ||||||
| 09/29/2023 | Vifor Pharma, Inc. | Veltassa (Drug), Korsuva | Food and Beverage | In-kind items and services | $24.37 | General |
| Category: Hyperkalemia | ||||||
| 08/30/2023 | Vifor Pharma, Inc. | Veltassa (Drug), Korsuva | Food and Beverage | In-kind items and services | $29.34 | General |
| Category: Hyperkalemia | ||||||
| 06/28/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $18.06 | General |
| Category: Cardio-renal | ||||||
| 06/19/2023 | Renalytix AI, Inc. | KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT (Device) | Food and Beverage | In-kind items and services | $24.75 | General |
| Category: INTERNAL MEDICINE | ||||||
| 06/14/2023 | Vifor Pharma, Inc. | Veltassa (Drug), Korsuva | Food and Beverage | In-kind items and services | $26.88 | General |
| Category: Hyperkalemia | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE DD-CKD INNO2VATE-CONVERSION | Otsuka Pharmaceutical Co., Ltd. | $514.44 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 724 | 1,714 | $266,967 | $165,873 |
| 2022 | 10 | 758 | 1,667 | $269,328 | $168,352 |
| 2021 | 13 | 894 | 2,020 | $318,487 | $200,182 |
| 2020 | 14 | 1,098 | 2,462 | $399,399 | $244,280 |
Total Patients
3,474
Total Services
7,863
Medicare Billing
$778,687
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 188 | 733 | $96,260 | $66,447 | 69.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 196 | 368 | $51,152 | $31,531 | 61.6% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 15 | 84 | $43,260 | $22,652 | 52.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 140 | 163 | $37,001 | $21,530 | 58.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 111 | 270 | $24,536 | $16,199 | 66.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 16 | 19 | $3,971 | $2,504 | 63.0% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 26 | 43 | $6,192 | $2,364 | 38.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 13 | 13 | $2,600 | $1,647 | 63.3% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 19 | 21 | $1,995 | $998.73 | 50.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 204 | 641 | $73,715 | $50,455 | 68.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 198 | 356 | $49,484 | $31,543 | 63.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 162 | 206 | $46,762 | $30,943 | 66.2% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 20 | 103 | $53,045 | $28,551 | 53.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 86 | 227 | $18,387 | $12,521 | 68.1% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 13 | 25 | $10,500 | $5,600 | 53.3% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 18 | 51 | $7,344 | $2,890 | 39.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 18 | 19 | $3,971 | $2,555 | 64.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 23 | 23 | $4,600 | $2,458 | 53.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 16 | 16 | $1,520 | $834.90 | 54.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 243 | 787 | $90,505 | $62,871 | 69.5% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 23 | 131 | $67,465 | $35,922 | 53.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 184 | 227 | $51,529 | $33,456 | 64.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 195 | 352 | $48,568 | $32,088 | 66.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 116 | 318 | $25,758 | $17,548 | 68.1% |
| 90935 | Hemodialysis procedure with one physician evaluation | Facility | 2021 | 33 | 76 | $10,944 | $4,375 | 40.0% |
About Dr. Muhammad Khan, MD
Dr. Muhammad Khan, MD is a Nephrology healthcare provider based in Cincinnati, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/22/2005. The National Provider Identifier (NPI) number assigned to this provider is 1568462299.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Muhammad Khan, MD has received a total of $3,793 in payments from pharmaceutical and medical device companies, with $355.23 received in 2024. These payments were reported across 166 transactions from 36 companies. The most common payment nature is "Food and Beverage" ($3,256).
As a Medicare-enrolled provider, Khan has provided services to 3,474 Medicare beneficiaries, totaling 7,863 services with total Medicare billing of $778,687. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Cincinnati, OH
- Active Since 07/22/2005
- Last Updated 07/01/2009
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1568462299
Products in Payments
- ACTHAR (Biological) $473.48
- Veltassa (Drug) $439.88
- KRYSTEXXA (Biological) $398.00
- Velphoro (Drug) $197.33
- JYNARQUE (Drug) $166.79
- Parsabiv (Biological) $162.18
- Auryxia (Drug) $126.92
- Kerendia (Drug) $122.28
- LOKELMA (Drug) $93.00
- Parsabiv (Drug) $92.58
- AURYXIA (Drug) $92.21
- KRYSTEXXA (Drug) $78.37
- FARXIGA (Drug) $77.59
- SYSTEM ONE (Device) $71.93
- TEGSEDI (Drug) $71.88
- Rayaldee (Drug) $52.05
- BENLYSTA (Biological) $45.24
- LUPKYNIS (Drug) $35.67
- CABENUVA (Biological) $35.34
- TARPEYO (Drug) $34.36
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Cincinnati
Francisco Flores, M.d, M.D
Nephrology — Payments: $163,331
Nephrology $163,331
Dr. Tahir Sajjad, M.d, M.D
Nephrology — Payments: $37,686
Nephrology $37,686
Dr. Arshdeep Tindni, M.d, M.D
Nephrology — Payments: $31,882
Nephrology $31,882
Dr. Joseph Kremer, M.d, M.D
Nephrology — Payments: $29,341
Nephrology $29,341
Dr. Karl Pembaur, M.d, M.D
Nephrology — Payments: $7,169
Nephrology $7,169
Dr. Ajay Srivastava, Md, MD
Nephrology — Payments: $6,069
Nephrology $6,069